Yoshifusa Aratake

Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019

Masahito Nakano, Hiroshi Yatsuhashi, Shigemune Bekki et al. · Scientific Reports · 2022 · 42 citations · Full text

Medicine, Oncology, Cancer Epidemiology +6

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Takashi Niizeki, Takayuki Tokunaga, Yuko Takami et al. · Targeted Oncology · 2022 · 41 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Helix 8 of leukotriene B ₄ receptor 1 inhibits ligand‐induced internalization

Yoshifusa Aratake, Toshiaki Okuno, Takehiko Matsunobu et al. · The FASEB Journal · 2012 · 28 citations

Life Sciences, Biochemistry, Pharmacology +17

The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis

Masayoshi Yada, Masayuki Miyazaki, Kenta Motomura et al. · Journal of Gastrointestinal Oncology · 2016 · 14 citations · Full text

Medicine, Hematology, Oncology +17

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study

Rie Sugimoto, Takeaki Satoh, Akihiro Ueda et al. · Medicine · 2022 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +15